Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
about
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from thRadioimmunotherapy with (131)i-rituximab in a patient with diffuse large B-cell lymphoma relapsed after treatment with (90)y-ibritumomab tiuxetan.Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma.Outpatient therapeutic nuclear oncology.Radioimmunotherapy with α-particle-emitting radionuclides.Thyroid dysfunction from antineoplastic agents.Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumorsStandard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma.Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications.Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.General overview of radioimmunotherapy of solid tumors.The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.Rituximab for the treatment of follicular lymphoma.Trial Watch: Anticancer radioimmunotherapy.Management of fear of radiation exposure in carers of outpatients treated with iodine-131.Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
P2860
Q33408270-8CDE9BEA-F5B2-4E25-B902-B7BE0DD8BAF7Q33415748-595F4FC8-773B-4703-AC80-FC14909909E6Q33434959-C77CD4C5-5791-4640-B492-E048FCAC2245Q34244990-A87F9825-AA46-4F5F-B0EC-7F522DD85232Q34419562-3528372B-724F-4BCD-86B9-77B7EB75F854Q35500038-52367730-8CFA-4493-BF39-A38BE806C70AQ35650530-A725ABEA-B36D-4297-9B0A-D66251BBB06EQ36563416-824900FA-ED2C-4C25-9741-AB64019E6EF9Q36948431-9A12BC39-672A-46A6-8692-FE67402F772DQ37132248-878FBE00-FF3B-472D-8D8B-E9A56E8F24A3Q38054112-E44F3288-2B4B-4E03-9DD4-13B3263343C2Q38103579-178C1629-0C91-42E3-BE2F-55C68399FD3BQ38215613-2203775F-4D5D-454B-B75D-86987E3D0112Q39360775-949118B4-C7C4-43A5-8EFA-ACAD5AAE785AQ42847992-BE5E2E5D-ACCB-4470-BF98-80F00A6A0DDAQ46645822-A17EB352-33C6-4ADC-8B07-761588469A0FQ52588132-084CB0FA-55B7-4B2A-A4DD-DE7D98DAB7A0Q53058794-537CA450-6B1A-42D4-B545-3417883D02E1Q55709954-58DB8D11-D092-4305-A93E-E7CE51D4B3E1
P2860
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Radioimmunotherapy of relapsed ...... e of 142 consecutive patients.
@ast
Radioimmunotherapy of relapsed ...... e of 142 consecutive patients.
@en
type
label
Radioimmunotherapy of relapsed ...... e of 142 consecutive patients.
@ast
Radioimmunotherapy of relapsed ...... e of 142 consecutive patients.
@en
prefLabel
Radioimmunotherapy of relapsed ...... e of 142 consecutive patients.
@ast
Radioimmunotherapy of relapsed ...... e of 142 consecutive patients.
@en
P1433
P1476
Radioimmunotherapy of relapsed ...... e of 142 consecutive patients.
@en
P2093
J Harvey Turner
Michael F Leahy
P356
10.1182/BLOOD-2010-02-269753
P407
P577
2010-09-23T00:00:00Z